Compare Uranium Energy Corp (UEC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Uranium Energy Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Uranium Energy Corp trades at $11.46 (market cap $5.67B), while State Street SPDR S&P Biotech ETF trades at $159.11. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| UEC | XBI | |
|---|---|---|
Market Cap | $5.67B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $20.14 | $164.28 |
52-Week Low | $9.04 | $86.92 |
Enterprise Value | $5.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Uranium Energy Corp (UEC) trades at $11.45, up 0.62% today, with a bullish technical signal supported by moving averages. The company shows significant financial challenges with a net income margin of -513.24% and negative cash flow from operations, though it maintains strong analyst support with 87.5% buy ratings. Recent news highlights insider selling but also optimistic long-term nuclear energy prospects.
UEC presents high-risk, high-reward potential driven by nuclear energy tailwinds, but faces substantial execution risks amid persistent losses and premium valuation. The stock's outlook hinges on production ramp-up success and uranium price movements, with current financials indicating cautious near-term investor sentiment despite bullish analyst consensus.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
